Akebia Therapeutics Ownership | Who Owns Akebia Therapeutics?


OverviewForecastRevenueFinancialsChartTranscripts

Akebia Therapeutics Ownership Summary


Akebia Therapeutics is owned by 32.23% institutional investors, 2.20% insiders, and 65.57% retail investors. Blackrock funding, inc. /de is the largest institutional shareholder, holding 7.18% of AKBA shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.72% of its assets in Akebia Therapeutics shares.

AKBA Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockAkebia Therapeutics32.23%2.20%65.57%
SectorHealthcare Stocks 57.43%9.41%33.16%
IndustryBiotech Stocks 69.02%8.92%22.06%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock funding, inc. /de15.10M7.18%$28.69M
Blackrock11.64M5.68%$11.87M
Vanguard group10.88M5.17%$20.68M
State street6.30M3.00%$11.98M
Alerce investment management5.75M2.73%$10.92M
Geode capital management4.80M2.28%$9.11M
Renaissance3.82M1.82%$7.26M
Jacobs levy equity management2.09M1.02%$2.14M
Qube research1.19M0.57%$2.26M
Connor, clark & lunn investment management1.03M0.49%$1.95M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Alerce investment management5.75M19.23%$10.92M
Exome asset management205.96K0.29%$391.32K
Diametric capital, lp88.11K0.11%$167.42K
Orchard capital management60.71K0.05%$115.35K
Alphamark advisors38.46K0.03%$73.00K
Wealth effects32.00K0.02%$60.80K
Eagle wealth strategies10.00K0.01%$19.00K
Prelude capital management93.15K0.01%$176.99K
Renaissance3.82M0.01%$7.26M
Two sigma securities40.83K0.01%$77.57K

Top Buyers

HolderShares% AssetsChange
Blackrock11.64M0.00%9.10M
State street6.30M0.00%2.87M
Vanguard group10.88M0.00%813.90K
Goldman sachs group1.00M0.00%516.92K
Jacobs levy equity management2.09M0.01%457.15K

Top Sellers

HolderShares% AssetsChange
Acadian asset management---4.06M
Eam investors---428.55K
Cubist systematic strategies---398.25K
Marshall wace, llp---247.07K
Boothbay fund management---240.00K

New Positions

HolderShares% AssetsChangeValue
Exome asset management205.96K0.29%205.96K$391.32K
Rafferty asset management179.75K0.00%179.75K$341.53M
Simplex trading128.98K0.00%128.98K$245.00K
Dimensional fund advisors lp125.68K0.00%125.68K$238.79K
Prelude capital management93.15K0.01%93.15K$176.99K

Sold Out

HolderChange
Capital performance advisors llp-68.00
Hexagon capital partners-186.00
Headlands-208.00
Laurel wealth advisors-229.00
Redwood wealth management group-300.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 20241244.20%67,787,36714.05%324.04%7018.64%22-15.38%
Sep 30, 20241189.26%59,390,7035.52%283.74%599.26%268.33%
Jun 30, 2024108-14.29%56,234,084-1.41%273.04%53-27.40%24-
Mar 31, 202412638.46%57,038,6344.20%303.55%7397.30%2414.29%
Dec 31, 20239113.75%54,737,4217.65%293.92%3732.14%21-

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv5.95M2.72%-
iShares Russell 2000 ETF5.50M2.52%-107.63K
Vanguard Institutional Extnd Mkt Idx Tr3.28M1.50%929.00
Fidelity Small Cap Index2.11M0.97%-13.25K
SPDR® S&P Biotech ETF1.92M0.88%14.54K
iShares Russell 2000 Value ETF1.79M0.82%-3.66K
State St Russell Sm/Mid Cp® Indx NL Cl C1.38M0.63%-
Fidelity Extended Market Index1.11M0.51%32.22K
Vanguard Russell 2000 ETF928.93K0.43%-61.30K
Federated Hermes MDT SCG Institutional809.71K0.37%-

Recent Insider Transactions


DateNameRoleActivityValue
Mar 03, 2025Butler John P. CEO and PresidentSell$84.93K
Mar 03, 2025Burke Steven Keith SVP, Chief Medical OfficerSell$13.07K
Feb 03, 2025Butler John P. CEO and PresidentSell$205.76K
Feb 03, 2025Butler John P. CEO and PresidentSell$97.16K
Feb 03, 2025Burke Steven Keith SVP, Chief Medical OfficerSell$48.87K

Insider Transactions Trends


DateBuySell
2025 Q1-8
2024 Q2-2
2024 Q1-10
2023 Q3-1
2023 Q2-4

AKBA Ownership FAQ


Who Owns Akebia Therapeutics?

Akebia Therapeutics shareholders are primarily institutional investors at 32.23%, followed by 2.20% insiders and 65.57% retail investors. The average institutional ownership in Akebia Therapeutics's industry, Biotech Stocks , is 69.02%, which Akebia Therapeutics falls below.

Who owns the most shares of Akebia Therapeutics?

Akebia Therapeutics’s largest shareholders are Blackrock funding, inc. /de (15.1M shares, 7.18%), Blackrock (11.64M shares, 5.68%), and Vanguard group (10.88M shares, 5.17%). Together, they hold 18.03% of Akebia Therapeutics’s total shares outstanding.

Does Blackrock own Akebia Therapeutics?

Yes, BlackRock owns 5.68% of Akebia Therapeutics, totaling 11.64M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 11.87M$. In the last quarter, BlackRock increased its holdings by 9.1M shares, a 358.35% change.

Who is Akebia Therapeutics’s biggest shareholder by percentage of total assets invested?

Alerce investment management is Akebia Therapeutics’s biggest shareholder by percentage of total assets invested, with 19.23% of its assets in 5.75M Akebia Therapeutics shares, valued at 10.92M$.

Who is the top mutual fund holder of Akebia Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Akebia Therapeutics shares, with 2.72% of its total shares outstanding invested in 5.95M Akebia Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools